NASHVILLE--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced two oral presentations and one ...

- Two presentations highlighting data on DaxibotulinumtoxinA for Injection, including one oral presentation showcasing new data on clinical immunogenicity from the SAKURA Phase 3 program, and one ...

NEW YORK — Adverse events following filler injection are typically linked to the filler’s characteristics, poor injection technique, and a lack of anatomical knowledge, according to an educational ...

Assessment of the bony orbit depth can help determine the best technique for filler injection of the tear trough and the palpebromalar groove, according to recently published study results. Yehia ...